Sunshine Biopharma Inc (NASDAQ:SBFM) — Market Cap & Net Worth
Market Cap & Net Worth: Sunshine Biopharma Inc (SBFM)
Sunshine Biopharma Inc (NASDAQ:SBFM) has a market capitalization of $2.54 Million ($2.54 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29804 globally and #6068 in its home market, demonstrating a -8.55% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sunshine Biopharma Inc's stock price $1.07 by its total outstanding shares 2378317 (2.38 Million). Also see Sunshine Biopharma Inc (SBFM) total assets for a full breakdown of the balance sheet.
Sunshine Biopharma Inc Market Cap History: 2015 to 2026
Sunshine Biopharma Inc's market capitalization history from 2015 to 2026. Data shows change from $2.38 Trillion to $2.54 Million (-71.63% CAGR). Also see Sunshine Biopharma Inc (SBFM) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Sunshine Biopharma Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #868 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #2777 of 3165 |
Weight: Sunshine Biopharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Sunshine Biopharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sunshine Biopharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Sunshine Biopharma Inc stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.08x
Sunshine Biopharma Inc's market cap is 0.08 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $304.42 Billion | $447.20K | -$2.16 Million | 680734.74x | N/A |
| 2019 | $8.56 Billion | $21.12K | -$1.66 Million | 405375.75x | N/A |
| 2020 | $14.94 Billion | $71.41K | -$2.78 Million | 209156.01x | N/A |
| 2021 | $55.61 Billion | $228.43K | -$12.44 Million | 243426.98x | N/A |
| 2022 | $3.04 Billion | $4.35 Million | -$26.74 Million | 700.53x | N/A |
| 2023 | $1.29 Billion | $24.09 Million | -$4.51 Million | 53.60x | N/A |
| 2024 | $7.13 Million | $34.87 Million | -$5.13 Million | 0.20x | N/A |
| 2025 | $2.93 Million | $36.31 Million | -$5.98 Million | 0.08x | N/A |
Competitor Companies of SBFM by Market Capitalization
Companies near Sunshine Biopharma Inc in the global market cap rankings as of September 18, 2026. Review SBFM goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Sunshine Biopharma Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #519 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #633 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #640 globally with a market cap of $43.16 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.62 Billion USD ( CN¥277.61 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #519 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #633 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #640 | GALDERMA GROUP AG | NYSE:GALDY | $43.16 Billion | $37.02 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.62 Billion | CN¥43.52 |
Sunshine Biopharma Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Sunshine Biopharma Inc's market cap moved from $2.38 Trillion to $ 2.54 Million, with a yearly change of -71.63%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.54 Million | -13.01% |
| 2025 | $2.93 Million | -59.00% |
| 2024 | $7.13 Million | -99.45% |
| 2023 | $1.29 Billion | -57.58% |
| 2022 | $3.04 Billion | -94.53% |
| 2021 | $55.61 Billion | +272.29% |
| 2020 | $14.94 Billion | +74.44% |
| 2019 | $8.56 Billion | -97.19% |
| 2018 | $304.42 Billion | -87.20% |
| 2017 | $2.38 Trillion | +56.25% |
| 2016 | $1.52 Trillion | -36.00% |
| 2015 | $2.38 Trillion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Sunshine Biopharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.54 Million USD |
| MoneyControl | $2.54 Million USD |
| MarketWatch | $2.54 Million USD |
| marketcap.company | $2.54 Million USD |
| Reuters | $2.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sunshine Biopharma Inc
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also … Read more